PROTACs
-
37:25WatchPut your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
-
Read
How to build an effective protein degrader
-
59:35WatchHow to improve the function of your PROTAC degrader by understanding ternary complex formation
Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
-
ReadWhy so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
-
Read
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
Read
Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust
-
35:47WatchImprove your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
Read10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
Trying to characterize ternary complex formation and cooperativity?
Find out more
In-solution measurements will help -
ReadProtein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
Discover tools to successfully characterize PROTAC binary and ternary complexes
Read more -
Read9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
ReadFor protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...
-
ReadTargeted protein degradation promises to lead the way to effective drugs for challenging targets
-
ReadMST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
-
ReadDdi1 is a ubiquitin-dependent protease
-
ReadAre you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
-
Read6 protein degradation conferences in 2021 you can’t afford to miss
Update: See what 2022 conferences you should watch for Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation...
-
17:10WatchTackle the high-hanging fruits in challenging drug discovery pipelines
There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
-
Read
Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus
-
Trying to characterize ternary complex formation and cooperativity?
Find out more
In-solution measurements will help -
ReadWhat are PROTACs: the game-changing modality that promises to tackle undruggable proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...
-
Discover tools to successfully characterize PROTAC binary and ternary complexes
Read more -
ReadSweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
-
Loading more...
